SCHOTT Pharma AG & Co. KGaA/€1SXP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA specializes in the design and manufacture of drug containment and delivery solutions for injectable medications, including prefillable glass and polymer syringes, cartridges, vials, and ampoules. Established as a standalone entity in August 2022 following its separation from SCHOTT AG, the company is headquartered in Mainz, Germany, and operates 16 manufacturing sites across Europe, North and South America, and Asia. With a portfolio of over 1,000 patents and a dedicated R&D center in Switzerland, SCHOTT Pharma focuses on developing innovative solutions to meet the evolving needs of the pharmaceutical industry. The company serves over 1,800 customers, including the top 30 pharmaceutical manufacturers for injectable drugs, and reported revenues of €821 million in the fiscal year 2022. SCHOTT Pharma is committed to sustainable development, aiming to achieve climate neutrality by 2030.
- Ticker
- €1SXP
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 5,002
- Headquarters
- Mainz, Germany
- Website
- www.schott-pharma.com
1SXP Metrics
BasicAdvanced
€3.8B
27.76
€0.90
0.98
€0.18
0.72%
Price and volume
Market cap
€3.8B
Beta
0.98
52-week high
€25.65
52-week low
€12.54
Average daily volume
64K
Dividend rate
€0.18
Financial strength
Current ratio
1.606
Quick ratio
0.737
Long term debt to equity
0.077
Total debt to equity
0.309
Dividend payout ratio (TTM)
19.90%
Interest coverage (TTM)
10.08%
Profitability
EBITDA (TTM)
249.297
Gross margin (TTM)
31.17%
Net profit margin (TTM)
13.40%
Operating margin (TTM)
16.45%
Effective tax rate (TTM)
21.85%
Revenue per employee (TTM)
€200,000
Management effectiveness
Return on assets (TTM)
6.49%
Return on equity (TTM)
14.67%
Valuation
Price to earnings (TTM)
27.755
Price to revenue (TTM)
3.709
Price to book
3.75
Price to tangible book (TTM)
3.87
Price to free cash flow (TTM)
68.645
Free cash flow yield (TTM)
1.46%
Free cash flow per share (TTM)
0.364
Dividend yield (TTM)
0.72%
Forward dividend yield
0.72%
Growth
Revenue change (TTM)
4.15%
Earnings per share change (TTM)
-7.25%
3-year revenue growth (CAGR)
5.21%
3-year earnings per share growth (CAGR)
-1.78%
3-year dividend per share growth (CAGR)
12.92%
What the Analysts think about 1SXP
Analyst ratings (Buy, Hold, Sell) for SCHOTT Pharma AG & Co. KGaA stock.
Analyst projections of the future price of SCHOTT Pharma AG & Co. KGaA stock.
Bulls say / Bears say
Third-quarter revenue grew 8.3% at constant currencies, and SCHOTT Pharma raised its 2026 growth forecast to 5–6% from 2–5%. This suggests momentum improved after a softer first half. (SCHOTT Pharma)
Drug Containment Solutions delivered 9.2% constant-currency growth over nine months, while its EBITDA rose 10.1% and its margin improved. The shift towards higher-value products is supporting both sales and profitability in this segment. (SCHOTT Pharma)
Demand for glass syringes used in GLP-1 medicines remains strong, while polymer syringes are gaining applications beyond mRNA. Expanded US vial capacity and new high-value product capacity give the company room to serve further demand. (Investing.com, SCHOTT Pharma)
Profitability has weakened despite sales growth: nine-month EBITDA fell 3.8% and the margin narrowed to 26.7% from 28.9%. Lower utilisation in drug delivery, production optimisation costs and a syringe inventory impairment weighed on results. (SCHOTT Pharma)
Around €15 million of the 2026 contribution from a glass-syringe customer agreement is a one-off and will not recur next year. That creates a tougher comparison and may make 2027 growth guidance fall short of the company’s 6–8% medium-term range. (Investing.com)
Deutsche Bank downgraded the shares to Hold, arguing that a roughly 70% rise year to date had left the valuation demanding and limited near-term upside. A strong share-price run raises the risk that good operating news is already reflected in the price. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
1SXP Financial Performance
Revenues and expenses
1SXP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing 1SXP
AllUSDEURGBP
Fund name | Fund size | €1SXP weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.07% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.07% |
Vanguard Germany All Cap£VGER | €258M | 0.05% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.